- Home
- SERA vs AVTX Comparison
SERA vs AVTX Comparison
Compare SERA & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SERA
- AVTX
- Stock Information
- Founded
- SERA 2008
- AVTX 2011
- Country
- SERA United States
- AVTX United States
- Employees
- SERA N/A
- AVTX N/A
- Industry
- SERA Precision Instruments
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- SERA Health Care
- AVTX Health Care
- Exchange
- SERA Nasdaq
- AVTX Nasdaq
- Market Cap
- SERA 70.4M
- AVTX 57.4M
- IPO Year
- SERA 2021
- AVTX 2015
- Fundamental
- Price
- SERA $2.87
- AVTX $6.66
- Analyst Decision
- SERA
- AVTX Strong Buy
- Analyst Count
- SERA 0
- AVTX 7
- Target Price
- SERA N/A
- AVTX $31.00
- AVG Volume (30 Days)
- SERA 135.5K
- AVTX 127.8K
- Earning Date
- SERA 08-06-2025
- AVTX 08-11-2025
- Dividend Yield
- SERA N/A
- AVTX N/A
- EPS Growth
- SERA N/A
- AVTX N/A
- EPS
- SERA N/A
- AVTX N/A
- Revenue
- SERA $115,000.00
- AVTX $441,000.00
- Revenue This Year
- SERA $390.13
- AVTX N/A
- Revenue Next Year
- SERA $440.54
- AVTX N/A
- P/E Ratio
- SERA N/A
- AVTX N/A
- Revenue Growth
- SERA N/A
- AVTX N/A
- 52 Week Low
- SERA $1.37
- AVTX $3.39
- 52 Week High
- SERA $9.13
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- SERA 53.01
- AVTX 70.62
- Support Level
- SERA $3.11
- AVTX $6.21
- Resistance Level
- SERA $3.32
- AVTX $6.89
- Average True Range (ATR)
- SERA 0.22
- AVTX 0.49
- MACD
- SERA -0.02
- AVTX 0.09
- Stochastic Oscillator
- SERA 29.69
- AVTX 80.71
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).